TY - JOUR
T1 - Predicting the Potency of Anti-Alzheimer’s Drug Combinations Using Machine Learning
AU - Anastasio, Thomas J.
N1 - Funding Information:
A grant from the Alzheimer?s Disease Research Fund, administered by the Illinois Department of Public Health (IDPH), supported this research. The IDPH was not involved in any phase of the project.
Funding Information:
Funding: A grant from the Alzheimer’s Disease Research Fund, administered by the Illinois Department of Public Health (IDPH), supported this research. The IDPH was not involved in any phase of the project.
Funding Information:
Acknowledgments: Access to data was provided by the Rush Alzheimer’s Disease Center (RADC) of the Rush University Medical Center in Chicago, Illinois. The data provided by RADC come from the participants in the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP). ROSMAP is supported by National Institute on Aging (NIA, of the National Institutes of Health) grants P30AG10161, R01AG15819, and R01AG17917, and by the Illinois Department of Public Health. Access to data was also provided by the National Alzheimer’s Coordinating Center (NACC). The NACC database is funded by NIA Grant U01 AG016976. NACC data are contributed by NIA-funded Alzheimer’s Disease Centers: P30 AG019610 (Principal Investigator (PI) Eric Reiman), P30 AG013846 (PI Neil Kowall), P30 AG062428-01 (PI James Leverenz) P50 AG008702 (PI Scott Small), P50 AG025688 (PI Allan Levey), P50 AG047266 (PI Todd Golde), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert), P30 AG062421-01 (PI Bradley Hyman), P30 AG062422-01 (PI Ronald Petersen), P50 AG005138 (PI Mary Sano), P30 AG008051 (PI Thomas Wisniewski), P30 AG013854 (PI Robert Vassar), P30 AG008017 (PI Jeffrey Kaye), P30 AG010161 (PI David Bennett), P50 AG047366 (PI Victor Henderson), P30 AG010129 (PI Charles DeCarli), P50 AG016573 (PI Frank LaFerla), P30 AG062429-01(PI James Brewer), P50 AG023501 (PI Bruce Miller), P30 AG035982 (PI Russell Swerdlow), P30 AG028383 (PI Linda Van Eldik), P30 AG053760 (PI Henry Paulson), P30 AG010124 (PI John Trojanowski), P50 AG005133 (PI Oscar Lopez), P50 AG005142 (PI Helena Chui), P30 AG012300 (PI Roger Rosenberg), P30 AG049638 (PI Suzanne Craft), P50 AG005136 (PI Thomas Grabowski), P30 AG062715-01 (PI Sanjay Asthana), P50 AG005681 (PI John Morris), and P50 AG047270 (PI Stephen Strittmatter).
Funding Information:
NACC encompasses the data from the 29 Alzheimer’s disease centers (ADCs) that are funded by the National Institute on Aging of the National Institutes of Health of the United States [18,19]. RADC is an ADC but most of its dataset comes from the participants in the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP) [20,21]. A small amount of legacy RADC data are included in NACC (less than 1.4% of total NACC data). All RADC data were removed from the NACC dataset for this study. The two datasets used for ML in this study are completely independent of each other (Supplementary Note S1).
PY - 2021/2
Y1 - 2021/2
N2 - Clinical trials of single drugs intended to slow the progression of Alzheimer’s Disease (AD) have been notoriously unsuccessful. Combinations of repurposed drugs could provide effective treatments for AD. The challenge is to identify potentially effective combinations. To meet this challenge, machine learning (ML) was used to extract the knowledge from two leading AD databases, and then “the machine” predicted which combinations of the drugs in common between the two databases would be the most effective as treatments for AD. Specifically, three-layered artificial neural networks (ANNs) with compound, gated units in their internal layer were trained using ML to predict the cognitive scores of participants, separately in either database, given other data fields including age, demographic variables, comorbidities, and drugs taken. The predictions from the separately trained ANNs were statistically highly significantly correlated. The best drug combinations, jointly determined from both sets of predictions, were high in nonsteroidal anti-inflammatory drugs; anticoagulant, lipid-lowering, and antihypertensive drugs; and female hormones. The results suggest that the neurodegenerative processes that underlie AD and other dementias could be effectively treated using a combination of repurposed drugs. Predicted drug combinations could be evaluated in clinical trials.
AB - Clinical trials of single drugs intended to slow the progression of Alzheimer’s Disease (AD) have been notoriously unsuccessful. Combinations of repurposed drugs could provide effective treatments for AD. The challenge is to identify potentially effective combinations. To meet this challenge, machine learning (ML) was used to extract the knowledge from two leading AD databases, and then “the machine” predicted which combinations of the drugs in common between the two databases would be the most effective as treatments for AD. Specifically, three-layered artificial neural networks (ANNs) with compound, gated units in their internal layer were trained using ML to predict the cognitive scores of participants, separately in either database, given other data fields including age, demographic variables, comorbidities, and drugs taken. The predictions from the separately trained ANNs were statistically highly significantly correlated. The best drug combinations, jointly determined from both sets of predictions, were high in nonsteroidal anti-inflammatory drugs; anticoagulant, lipid-lowering, and antihypertensive drugs; and female hormones. The results suggest that the neurodegenerative processes that underlie AD and other dementias could be effectively treated using a combination of repurposed drugs. Predicted drug combinations could be evaluated in clinical trials.
KW - Alzheimer’s disease
KW - Artificial intelligence
KW - Artificial neural network
KW - Drug combination
KW - Drug repurposing
KW - Machine learning
KW - Multifactorial disorder
KW - Neurodegeneration
KW - Polypharmacy
UR - http://www.scopus.com/inward/record.url?scp=85100115882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100115882&partnerID=8YFLogxK
U2 - 10.3390/pr9020264
DO - 10.3390/pr9020264
M3 - Article
SN - 2227-9717
VL - 9
SP - 1
EP - 17
JO - Processes
JF - Processes
IS - 2
M1 - 264
ER -